basically the comments were correct -there is a statistically principle explaining why phase III seldom match phase I: regression to the mean. Moreover right on target that 65 ve 75% won't change clinical practice in which desire to do no harm puts heavy weight on side effects. Finally advantage of familiarity for 1st approved drug of that generation is being entirely neglected. Simponi has better efficacy numbers than Humira or Enbrel, but has anyone changed their practice patterns to use it? no! -the competition in development is nearly irrelevant.